Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)

China flag China · Delayed Price · Currency is CNY
39.72
-1.17 (-2.86%)
At close: Mar 9, 2026
68.88%
Market Cap 6.32B
Revenue (ttm) 871.31M
Net Income (ttm) 57.12M
Shares Out 159.01M
EPS (ttm) 0.36
PE Ratio 109.23
Forward PE n/a
Dividend 0.60 (1.47%)
Ex-Dividend Date Jun 9, 2025
Volume 1,859,800
Average Volume 2,334,834
Open 40.38
Previous Close 40.89
Day's Range 39.43 - 40.52
52-Week Range 22.71 - 67.98
Beta 0.52
RSI 41.19
Earnings Date Apr 23, 2026

About SHA:603590

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; and KC1036, which is in phase 2 clinical tr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 668
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603590
Full Company Profile

Financial Performance

In 2024, SHA:603590's revenue was 825.40 million, a decrease of -10.28% compared to the previous year's 920.01 million. Earnings were 42.22 million, a decrease of -71.94%.

Financial Statements

News

There is no news available yet.